Trials & R&D · first seen 6h ago, updated 6h ago
China biotechs engineer the next generation of oncology therapies
New collaborations involving Henlius, Amberstone, Sanyou Bio and Novocodex highlight efforts to improve the safety, precision and efficacy of two fast-growing oncology modalities, T-cell engagers and antibody-drug conjugates.
Summary from BioWorld Articles.
Coverage 1 article · 1 outlet
-
BioWorld ArticlesChina biotechs engineer the next generation of oncology therapies